FACTSET RESEARCH SYSTEMS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that FACTSET RESEARCH SYSTEMS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Aug 31, 2019 | $1.44B | Oct 30, 2019 |
| FY2018 | Aug 31, 2018 | $345.86M | Oct 30, 2018 |
| FY2018 | May 31, 2018 | $339.91M | Oct 30, 2018 |
| FY2018 | Feb 28, 2018 | $335.23M | Oct 30, 2018 |
| FY2018 | Nov 30, 2017 | $329.14M | Oct 30, 2018 |
| FY2018 | Aug 31, 2017 | $326.64M | Oct 30, 2018 |
| FY2018 | May 31, 2017 | $312.12M | Oct 30, 2018 |
| FY2018 | Feb 28, 2017 | $294.35M | Oct 30, 2018 |
| FY2018 | Nov 30, 2016 | $288.06M | Oct 30, 2018 |
| FY2017 | Aug 31, 2016 | $287.29M | Oct 30, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $2.32B | Oct 22, 2025 |
| FY2025 | Aug 31, 2024 | $2.20B | Oct 22, 2025 |
| FY2025 | Aug 31, 2023 | $2.09B | Oct 22, 2025 |
| FY2024 | Aug 31, 2022 | $1.84B | Oct 29, 2024 |
| FY2023 | Aug 31, 2021 | $1.59B | Oct 27, 2023 |
| FY2020 | Aug 31, 2020 | $383.59M | Oct 29, 2020 |
| FY2020 | May 31, 2020 | $374.08M | Oct 29, 2020 |
| FY2020 | Feb 28, 2020 | $369.78M | Oct 29, 2020 |
| FY2020 | Nov 30, 2019 | $366.66M | Oct 29, 2020 |
| FY2020 | Aug 31, 2019 | $364.28M | Oct 29, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $597.04M | Oct 22, 2025 |
| FY2025 | Aug 31, 2024 | $537.13M | Oct 22, 2025 |
| FY2025 | Aug 31, 2023 | $468.17M | Oct 22, 2025 |
| FY2024 | Aug 31, 2022 | $396.92M | Oct 29, 2024 |
| FY2023 | Aug 31, 2021 | $399.59M | Oct 27, 2023 |
| FY2020 | Aug 31, 2020 | $89.08M | Oct 29, 2020 |
| FY2020 | May 31, 2020 | $101.22M | Oct 29, 2020 |
| FY2020 | Feb 28, 2020 | $88.69M | Oct 29, 2020 |
| FY2020 | Nov 30, 2019 | $93.96M | Oct 29, 2020 |
| FY2020 | Aug 31, 2019 | $91.53M | Oct 29, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $748.30M | Oct 22, 2025 |
| FY2025 | Aug 31, 2024 | $701.30M | Oct 22, 2025 |
| FY2025 | Aug 31, 2023 | $629.21M | Oct 22, 2025 |
| FY2024 | Aug 31, 2022 | $475.48M | Oct 29, 2024 |
| FY2023 | Aug 31, 2021 | $474.04M | Oct 27, 2023 |
| FY2020 | Aug 31, 2020 | $98.58M | Oct 29, 2020 |
| FY2020 | May 31, 2020 | $121.64M | Oct 29, 2020 |
| FY2020 | Feb 28, 2020 | $106.26M | Oct 29, 2020 |
| FY2020 | Nov 30, 2019 | $113.19M | Oct 29, 2020 |
| FY2020 | Aug 31, 2019 | $111.57M | Oct 29, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $300.70M | Oct 22, 2025 |
| FY2025 | Aug 31, 2024 | $265.20M | Oct 22, 2025 |
| FY2025 | Aug 31, 2023 | $267.40M | Oct 22, 2025 |
| FY2024 | Aug 31, 2022 | $255.10M | Oct 29, 2024 |
| FY2023 | Aug 31, 2021 | $250.10M | Oct 27, 2023 |
| FY2022 | Aug 31, 2020 | $224.00M | Oct 21, 2022 |
| FY2020 | Aug 31, 2019 | $214.70M | Oct 29, 2020 |
| FY2020 | Aug 31, 2018 | $217.10M | Oct 29, 2020 |
| FY2019 | Aug 31, 2017 | $215.00M | Oct 30, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $475.66M | Oct 22, 2025 |
| FY2025 | Aug 31, 2024 | $489.81M | Oct 22, 2025 |
| FY2025 | Aug 31, 2023 | $483.08M | Oct 22, 2025 |
| FY2024 | Aug 31, 2022 | $433.03M | Oct 29, 2024 |
| FY2023 | Aug 31, 2021 | $331.00M | Oct 27, 2023 |
| FY2020 | Aug 31, 2020 | $101.45M | Oct 29, 2020 |
| FY2020 | May 31, 2020 | $81.74M | Oct 29, 2020 |
| FY2020 | Feb 28, 2020 | $87.31M | Oct 29, 2020 |
| FY2020 | Nov 30, 2019 | $88.52M | Oct 29, 2020 |
| FY2020 | Aug 31, 2019 | $84.99M | Oct 29, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $726.26M | Oct 22, 2025 |
| FY2025 | Aug 31, 2024 | $700.34M | Oct 22, 2025 |
| FY2025 | Aug 31, 2023 | $645.57M | Oct 22, 2025 |
| FY2024 | Aug 31, 2022 | $538.28M | Oct 29, 2024 |
| FY2023 | Aug 31, 2021 | $555.23M | Oct 27, 2023 |
| FY2022 | Aug 31, 2020 | $505.84M | Oct 21, 2022 |
| FY2021 | Aug 31, 2019 | $427.14M | Oct 22, 2021 |
| FY2020 | Aug 31, 2018 | $385.67M | Oct 29, 2020 |
| FY2019 | Aug 31, 2017 | $320.53M | Oct 30, 2019 |
| FY2018 | Aug 31, 2016 | $331.14M | Oct 30, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Aug 31, 2023 | $60.79M | Oct 27, 2023 |
| FY2023 | Aug 31, 2022 | $51.16M | Oct 27, 2023 |
| FY2023 | Aug 31, 2021 | $61.33M | Oct 27, 2023 |
| FY2022 | Aug 31, 2020 | $77.64M | Oct 21, 2022 |
| FY2021 | Aug 31, 2019 | $59.37M | Oct 22, 2021 |
| FY2020 | Aug 31, 2018 | $33.52M | Oct 29, 2020 |
| FY2019 | Aug 31, 2017 | $36.86M | Oct 30, 2019 |
| FY2018 | Aug 31, 2016 | $47.74M | Oct 30, 2018 |
| FY2017 | Aug 31, 2015 | $25.68M | Oct 30, 2017 |
| FY2016 | Aug 31, 2014 | $17.74M | Oct 31, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $4.30B | Oct 22, 2025 |
| FY2025 | Aug 31, 2024 | $4.06B | Oct 22, 2025 |
| FY2025 | Aug 31, 2023 | $3.96B | Oct 22, 2025 |
| FY2023 | Aug 31, 2022 | $4.01B | Oct 27, 2023 |
| FY2022 | Aug 31, 2021 | $2.22B | Oct 21, 2022 |
| FY2021 | Aug 31, 2020 | $2.08B | Oct 22, 2021 |
| FY2020 | Aug 31, 2019 | $1.56B | Oct 29, 2020 |
| FY2019 | Aug 31, 2018 | $1.42B | Oct 30, 2019 |
| FY2019 | Aug 31, 2017 | $1.41B | Oct 30, 2019 |
| FY2018 | Aug 31, 2016 | $1.02B | Oct 30, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $2.12B | Oct 22, 2025 |
| FY2025 | Aug 31, 2024 | $2.14B | Oct 22, 2025 |
| FY2024 | Aug 31, 2023 | $2.34B | Oct 29, 2024 |
| FY2023 | Aug 31, 2022 | $2.68B | Oct 27, 2023 |
| FY2022 | Aug 31, 2021 | $1.21B | Oct 21, 2022 |
| FY2021 | Aug 31, 2020 | $1.19B | Oct 22, 2021 |
| FY2020 | Aug 31, 2019 | $887.87M | Oct 29, 2020 |
| FY2019 | Aug 31, 2018 | $893.55M | Oct 30, 2019 |
| FY2018 | Aug 31, 2017 | $853.62M | Oct 30, 2018 |
| FY2017 | Aug 31, 2016 | $501.78M | Oct 30, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $2.19B | Oct 22, 2025 |
| FY2025 | Aug 31, 2024 | $1.91B | Oct 22, 2025 |
| FY2025 | Aug 31, 2023 | $1.62B | Oct 22, 2025 |
| FY2025 | Aug 31, 2022 | $1.33B | Oct 22, 2025 |
| FY2024 | Aug 31, 2021 | $1.02B | Oct 29, 2024 |
| FY2023 | Aug 31, 2020 | $896.38M | Oct 27, 2023 |
| FY2022 | Aug 31, 2019 | $672.26M | Oct 21, 2022 |
| FY2021 | Aug 31, 2018 | $525.90M | Oct 22, 2021 |
| FY2020 | Aug 31, 2017 | $559.69M | Oct 29, 2020 |
| FY2019 | Aug 31, 2016 | $517.38M | Oct 30, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $1.28B | Oct 22, 2025 |
| FY2025 | Aug 31, 2024 | $1.01B | Oct 22, 2025 |
| FY2025 | Aug 31, 2023 | $1.00B | Oct 22, 2025 |
| FY2024 | Aug 31, 2022 | $965.85M | Oct 29, 2024 |
| FY2023 | Aug 31, 2021 | $754.21M | Oct 27, 2023 |
| FY2022 | Aug 31, 2020 | $709.70M | Oct 21, 2022 |
| FY2021 | Aug 31, 2019 | $685.73M | Oct 22, 2021 |
| FY2020 | Aug 31, 2018 | $701.83M | Oct 29, 2020 |
| FY2019 | Aug 31, 2017 | $707.56M | Oct 30, 2019 |
| FY2018 | Aug 31, 2016 | $452.92M | Oct 30, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $2.32B | Oct 22, 2025 |
| FY2025 | Aug 31, 2024 | $1.89B | Oct 22, 2025 |
| FY2024 | Aug 31, 2023 | $1.51B | Oct 29, 2024 |
| FY2023 | Aug 31, 2022 | $1.18B | Oct 27, 2023 |
| FY2022 | Aug 31, 2021 | $912.52M | Oct 21, 2022 |
| FY2021 | Aug 31, 2020 | $633.15M | Oct 22, 2021 |
| FY2020 | Aug 31, 2019 | $373.23M | Oct 29, 2020 |
| FY2019 | Aug 31, 2018 | $122.84M | Oct 30, 2019 |
| FY2018 | Aug 31, 2017 | $1.46B | Oct 30, 2018 |
| FY2017 | Aug 31, 2016 | $1.28B | Oct 30, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $337.65M | Oct 22, 2025 |
| FY2025 | Aug 31, 2024 | $422.98M | Oct 22, 2025 |
| FY2025 | Aug 31, 2023 | $425.44M | Oct 22, 2025 |
| FY2023 | Aug 31, 2022 | $503.27M | Oct 27, 2023 |
| FY2022 | Aug 31, 2021 | $681.87M | Oct 21, 2022 |
| FY2021 | Aug 31, 2020 | $585.61M | Oct 22, 2021 |
| FY2020 | Aug 31, 2019 | $359.80M | Oct 29, 2020 |
| FY2019 | Aug 31, 2018 | $208.62M | Oct 30, 2019 |
| FY2019 | Aug 31, 2017 | $194.73M | Oct 30, 2019 |
| FY2019 | Aug 31, 2016 | $228.41M | Oct 30, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $1.37B | Oct 22, 2025 |
| FY2025 | Aug 31, 2024 | $1.37B | Oct 22, 2025 |
| FY2024 | Aug 31, 2023 | $1.61B | Oct 29, 2024 |
| FY2023 | Aug 31, 2022 | $1.98B | Oct 27, 2023 |
| FY2022 | Aug 31, 2021 | $574.54M | Oct 21, 2022 |
| FY2021 | Aug 31, 2020 | $574.35M | Oct 22, 2021 |
| FY2020 | Aug 31, 2019 | $574.17M | Oct 29, 2020 |
| FY2019 | Aug 31, 2018 | $574.78M | Oct 30, 2019 |
| FY2018 | Aug 31, 2017 | $575.00M | Oct 30, 2018 |
| FY2017 | Aug 31, 2016 | $300.00M | Oct 30, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 15 | Oct 22, 2025 |
| FY2025 | Aug 31, 2024 | 14 | Oct 22, 2025 |
| FY2025 | Aug 31, 2023 | 12 | Oct 22, 2025 |
| FY2024 | Aug 31, 2022 | 10 | Oct 29, 2024 |
| FY2023 | Aug 31, 2021 | 10 | Oct 27, 2023 |
| FY2022 | Aug 31, 2020 | 9 | Oct 21, 2022 |
| FY2021 | Aug 31, 2019 | 9 | Oct 22, 2021 |
| FY2020 | Aug 31, 2018 | 6 | Oct 29, 2020 |
| FY2019 | Aug 31, 2017 | 6 | Oct 30, 2019 |
| FY2018 | Aug 31, 2016 | 8 | Oct 30, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 15 | Oct 22, 2025 |
| FY2025 | Aug 31, 2024 | 13 | Oct 22, 2025 |
| FY2025 | Aug 31, 2023 | 12 | Oct 22, 2025 |
| FY2024 | Aug 31, 2022 | 10 | Oct 29, 2024 |
| FY2023 | Aug 31, 2021 | 10 | Oct 27, 2023 |
| FY2020 | Aug 31, 2020 | 2 | Oct 29, 2020 |
| FY2020 | May 31, 2020 | 2 | Oct 29, 2020 |
| FY2020 | Feb 28, 2020 | 2 | Oct 29, 2020 |
| FY2020 | Nov 30, 2019 | 2 | Oct 29, 2020 |
| FY2020 | Aug 31, 2019 | 2 | Oct 29, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 37.65M | Oct 22, 2025 |
| FY2025 | Aug 31, 2024 | 37.95M | Oct 22, 2025 |
| FY2024 | Aug 31, 2023 | 38.03M | Oct 29, 2024 |
| FY2023 | Aug 31, 2022 | 38.04M | Oct 27, 2023 |
| FY2022 | Aug 31, 2021 | 37.62M | Oct 21, 2022 |
| FY2022 | Aug 31, 2020 | 38.03M | Oct 21, 2022 |
| FY2022 | Aug 31, 2019 | 38.12M | Oct 21, 2022 |
| FY2021 | Aug 31, 2018 | 38.19M | Oct 22, 2021 |
| FY2020 | Aug 31, 2017 | 39.02M | Oct 29, 2020 |
| FY2019 | Aug 31, 2016 | 40.04M | Oct 30, 2019 |